---
$id: https://graph.org.ai/products/commodity/51202411
$type: Product
source: UNSPSC
code: "51202411"
title: "Natalizumab"
class: "51202400"
classTitle: "Immunosupressant antibodies"
family: "51200000"
familyTitle: "Immunomodulating drugs"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Natalizumab

**UNSPSC Code**: 51202411
**Class**: [Immunosupressant antibodies](Immunosupressant antibodies.mdx)
**Family**: [Immunomodulating drugs](../Immunomodulating drugs.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes an immunosuppressant and antineoplastic monoclonal antibody and multiple sclerosis treatment, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 3JB47N2Q2P. The term NATALIZUMAB is an International Non-Proprietary Name or INN. European Medicines Agency schedules natalizumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22282. Most nations, for tariff and trade purposes, schedule natalizumab under HS 30021091 and SITC 54163. As of Q4 2014, NATALIZUMAB remains US FDA's Preferred Term for this commodity. Natalizumab bears US NLM identifiers UMLS ID C0665297 and NCI Concept Code C77862. SMILES: none.

